Amedisys Inc. (NASDAQ:AMED) went down by -11.49% from its latest closing price compared to the recent 1-year high of $276.21. The company’s stock price has collected -3.68% of loss in the last five trading sessions.
Is It Worth Investing in Amedisys Inc. (NASDAQ :AMED) Right Now?
Amedisys Inc. (NASDAQ:AMED) scored a price-to-earnings ratio above its average ratio, recording 18.51 x from its present earnings ratio. Plus, the 36-month beta value for AMED is at 0.81. Opinions of the stock are interesting as 9 analysts out of 16 who provided ratings for Amedisys Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $163.20, which is $65.31 above the current price. AMED currently public float of 32.00M and currently shorts hold a 4.70% ratio of that float. Today, the average trading volume of AMED was 332.57K shares.
AMED’s Market Performance
AMED stocks went down by -3.68% for the week, with a monthly drop of -12.94% and a quarterly performance of -33.33%, while its annual performance rate touched -56.23%. The volatility ratio for the week stands at 5.14% while the volatility levels for the past 30 days are set at 4.59% for Amedisys Inc. The simple moving average for the period of the last 20 days is -7.95% for AMED stocks with a simple moving average of -28.29% for the last 200 days.
Analysts’ Opinion of AMED
Many brokerage firms have already submitted their reports for AMED stocks, with BofA Securities repeating the rating for AMED by listing it as a “Underperform.” The predicted price for AMED in the upcoming period, according to BofA Securities is $102 based on the research report published on June 21st of the current year 2022.
UBS, on the other hand, stated in their research note that they expect to see AMED reach a price target of $168. The rating they have provided for AMED stocks is “Neutral” according to the report published on March 01st, 2022.
BMO Capital Markets gave a rating of “Outperform” to AMED, setting the target price at $190 in the report published on February 25th of the current year.
AMED Trading at -15.53% from the 50-Day Moving Average
After a stumble in the market that brought AMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.11% of loss for the given period.
Volatility was left at 4.59%, however, over the last 30 days, the volatility rate increased by 5.14%, as shares sank -15.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.76% lower at present.
During the last 5 trading sessions, AMED fell by -3.68%, which changed the moving average for the period of 200-days by -42.62% in comparison to the 20-day moving average, which settled at $115.75. In addition, Amedisys Inc. saw -33.64% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at AMED starting from Kemmerly David L, who sale 2,500 shares at the price of $177.31 back on Mar 29. After this action, Kemmerly David L now owns 16,336 shares of Amedisys Inc., valued at $443,285 using the latest closing price.
LECHLEITER RICHARD A, the Director of Amedisys Inc., purchase 1,000 shares at $141.25 during a trade that took place back on Nov 30, which means that LECHLEITER RICHARD A is holding 9,368 shares at $141,250 based on the most recent closing price.
Stock Fundamentals for AMED
Current profitability levels for the company are sitting at:
- +11.12 for the present operating margin
- +42.90 for the gross margin
The net margin for Amedisys Inc. stands at +9.44. Equity return is now at value 20.80, with 10.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.95.